As a leader in muscle biology research, we are dedicated to our mission of improving the lives of people confronting devastating diseases of impaired muscle function.
Company Recently Announced Option Right for Tirasemtiv and Expansion of Global Collaboration for CK-2127107 in ALS with Astellas Nearing Completion of Patient Enrollment in VITALITY-ALS SOUTH SAN FRANCISCO, Calif., July 28, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) reported total revenues for the second quarter of 2016 were $5.8 million,...READ MORE ›
People fighting amyotrophic lateral sclerosis have few treatment options; we are dedicated to changing the progression of this fatal disease.
Heart failure death and disability rates continue to rise, despite current treatment options. With Amgen, we are developing a novel therapy that may improve cardiac performance in people with heart failure.
People suffering from spinal muscular atrophy experience devastating loss of muscle function. With Astellas, we are working on a treatment that may enhance skeletal muscle performance in these and other patients.